Following on from information provided to NICE by the company in April 2020 the appraisal of Galcanezumab for preventing episodic cluster headache [ID1212] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
Status | Discontinued |
Technology type | Medicine |
Decision | Selected |
Process | TA |
ID number | 1212 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
16 November 2022 | Following on from information provided to NICE by the company in April 2020 the appraisal of Galcanezumab for preventing episodic cluster headache [ID1212] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
16 November 2022 | Discontinued. Following on from information provided to NICE by the company in April 2020 the appraisal of Galcanezumab for preventing episodic cluster headache [ID1212] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
24 February 2021 | Expected publication |
17 April 2020 | The Department for Health and Social Care has asked NICE to conduct an appraisal of Galcanezumab for preventing episodic cluster headache. However, the company have advised that The European Medicines Agency Committee for Medicinal Products (CHMP) have issued a negative opinion for galcanezumab injection for the preventive treatment of episodic cluster headache in adults in the European Union. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes. |
17 April 2020 | Suspended. Topic is suspended |
12 December 2019 | In progress. Referred: April 29 2019 |
12 December 2019 | Following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early April 2020. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
13 November 2018 - 11 December 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual